Skip to main content
Premium Trial:

Request an Annual Quote

Weakness in Proteomics and Life Science Research Contributes to Disappointing Q2 for Waters


Funding cuts for government and academic researchers led to weakened demand for tools for "cutting-edge proteomics and life science research," said Waters CEO Douglas Berthiaume during a conference call discussing the company's second-quarter results.

That, along with orders delayed in anticipation of the launch of Waters' new Synapt G2-S mass spectrometer at the American Society for Mass Spectrometry annual meeting in June, led to slowing demand in Q2 for the company's existing Synapt machines, Berthiaume said.

He noted that the firm expects the government and academic markets will continue to be flat but that its "innovative new systems, especially in high-end mass spectrometry, will allow [Waters] to compete favorably within this more challenging funding environment."

"The second-half results will probably be most affected by the Synapt G2-S," Berthiaume said. "We're expecting significant shipments of that at the end of the third quarter into the fourth quarter."

For the quarter Waters posted $447.6 million in revenue, up 14 percent from $391.1 million a year ago, but short of Wall Street's consensus estimate of $451.1 million.

The company also fell short of Wall Street's earnings-per-share expectations as net income for the quarter came in at $100.1 million, or $1.07 per share. On an adjusted basis EPS was $1.08, below analysts' expectations of $1.14. The company's profit for the prior year's second quarter was $84.9 million, or $.90 per share.

Waters' R&D spending rose 11 percent to $23.0 million from $20.8 million a year ago.

It ended the second quarter with $1.12 billion in cash, cash equivalents, and short-term investments.

The Scan

Should've Been Spotted Sooner

Scientists tell the Guardian that SARS-CoV-2 testing issues at a UK lab should have been noticed earlier.

For Martian Fuel

Researchers have outlined a plan to produce rocket fuel on Mars that uses a combination of sunlight, carbon dioxide, frozen water, cyanobacteria, and engineered E. coli, according to Gizmodo.

To Boost Rapid Testing

The Washington Post writes that new US programs aim to boost the availability of rapid at-home SARS-CoV-2 tests.

PNAS Papers on Strawberry Evolution, Cell Cycle Regulators, False-Positive Triplex Gene Editing

In PNAS this week: strawberry pan-genome, cell cycle-related roles for MDM2 and MDMX, and more.